Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A. Ascierto, Paola Queirolo, Ester Simeone et al.|Journal of Translational Medicine|2014Cited by 164
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanomaMichele Del Vecchio, Michele Maio, Pier Francesco Ferrucci et al.|European Journal of Cancer|2013Cited by 157
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access ProgramPaolo A. Ascierto, Michele Maio, Ester Simeone et al.|Cancer Investigation|2014Cited by 105
Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferonA. Paolo, Paola Queirolo, Vanna Chiarion‐Sileni et al.|Journal of Chemotherapy|2013Cited by 20
Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).Anna Maria Di Giacomo, Vanna Chiarion‐Sileni, Antonio Maria Grimaldi et al.|Journal of Clinical Oncology|2013Cited by 15